Saltar al contenido
Merck

P-903

Supelco

Protriptyline hydrochloride solution

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C19H21N · HCl
Número de CAS:
Peso molecular:
299.84
Número CE:
Número MDL:
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
NACRES:
NA.24

grado

certified reference material

Nivel de calidad

Formulario

liquid

Características

Snap-N-Spike®/Snap-N-Shoot®

envase

ampule of 1 mL

fabricante / nombre comercial

Cerilliant®

concentración

1.0 mg/mL in methanol (as free base)

técnicas

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

aplicaciones

clinical testing

Formato

single component solution

temp. de almacenamiento

2-8°C

cadena SMILES

CNCCCC1C2=C(C=CC=C2)C=CC3=C1C=CC=C3.[H]Cl

InChI

1S/C19H21N.ClH/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19;/h2-5,7-10,12-13,19-20H,6,11,14H2,1H3;1H

Clave InChI

OGQDIIKRQRZXJH-UHFFFAOYSA-N

Información sobre el gen

Descripción general

Protriptyline is a second generation tricyclic antidepressant (TCA) marketed under the trade name Vivactil®, for treatment of major depression and ADHD. This certified Snap-N-Spike® solution is applicable for use in LC/MS or GC/MS applications in clinical toxicology, forensic analysis, or urine drug testing. Protriptyline is unique among TCAs, since it has energizing, rather than sedating effects.

Información legal

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Vivactil is a registered trademark of Teva Women's Health, Inc.

Palabra de señalización

Danger

Clasificaciones de peligro

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Órganos de actuación

Eyes

Código de clase de almacenamiento

3 - Flammable liquids

Clase de riesgo para el agua (WGK)

WGK 1

Punto de inflamabilidad (°F)

49.5 °F - closed cup

Punto de inflamabilidad (°C)

9.7 °C - closed cup


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

K E Kinnamon et al.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 216(3), 424-428 (1997-12-24)
Forty-nine "standard" compounds known to be useful in the treatment of other diseases were tested for their suppressive activity against the trypomastigotes of Trypanosoma cruzi-infected mice. The most active was the antidepressant protriptyline, which was almost three times as effective
Y Huang
British journal of pharmacology, 117(3), 533-539 (1996-02-01)
1 The effects of noradrenaline (NA) uptake inhibitors on contractions induced by NA, high K+, and 12-O-tetradecanoylphorbol-13-acetate (TPA) in rat isolated aorta were investigated. 2 Protriptyline (0.3 microM) and amitriptyline (0.3 microM) produced an approximately parallel shift to the right
Malcolm Kohler et al.
Expert opinion on investigational drugs, 18(5), 647-656 (2009-04-25)
Currently the treatment of choice for symptomatic obstructive sleep apnoea (OSA) is continuous positive airway pressure (CPAP). Some patients with OSA do not tolerate CPAP or have insufficiently severe symptoms to justify its use; for these patients, drug therapy would
Nonsurgical management of the obstructive sleep apnea patient.
W K Thornton et al.
Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 54(9), 1103-1108 (1996-09-01)
T E Wilens et al.
Journal of the American Academy of Child and Adolescent Psychiatry, 35(11), 1485-1490 (1996-11-01)
To evaluate the potential benefit of the tricyclic antidepressant, protriptyline, in the treatment of children and adolescents with attention-deficit hyperactivity disorder (ADHD). All clinic patients in an outpatient pediatric psychopharmacology unit treated with protriptyline for ADHD were monitored for response

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico